News

The randomized, double-blind REFLECTIONS B3281006 clinical trial assessed the efficacy, safety, pharmacokinetics and immunogenicity of PF-05280586 in comparison to rituximab. It demonstrated equivalence of the biosimilar candidate in

FlexFactory, which is a biomanufacturing platform based on single-use technologies, will be deployed at Clover’s facility in Changxing of Zhejiang. The facility is being built for the production of biological

Enochian is developing an innovative proprietary technology in the field of HIV/AIDS. DanDrit believes that through the acquisition, Enochian's technology will enhance DanDrit's research and development efforts and

The decision follows a positive recommendation for Orphan Designation from the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP). In Europe, an Orphan Designation is granted

MPS IIIA, a rare metabolic disorder also known as Sanfilippo syndrome type A, affects children from an early age. The condition results in severe deterioration of the central nervous

Under the deal, Celgene will purchase Juno’s stock by paying $87 per share in cash. Juno is engaged in the development of novel cellular immunotherapies for the treatment

The EC approval marks Bristol-Myers Squibb’s first pediatric indication for an Immuno-Oncology medicine in the European Union (EU) and allows for the marketing of Yervoy for this indication

Under the terms of the agreement Abcam will obtain the exclusive rights to the product portfolio of Spring Bioscience Corporation in the research use only (RUO) field of

Bioverativ, which is a spin-off from biotech firm Biogen, focuses on therapies for hemophilia and other rare blood disorders. As per the merger deal terms, Sanofi will start